Improving Early Phase Oncology Trial Execution With A Site-First Approach

By Jim Routt, Chief Operating Officer

A clinical trial can be won or lost before anyone is enrolled. For a person facing cancer, time is not an abstract metric, and every week lost to a delayed site opening is a week that matters. Yet many of those delays are built in upstream: protocol changes that arrive late, messages that never quite line up, and little understanding of what a site can truly carry out.

Sites running first-in-human and dose-finding studies are juggling more complexity with fewer resources, and they keep asking one simple question: can we do this well for our patients? Disease-focused site networks can speed up activation, support enrollment, and strengthen data quality, but only when they help shape the study rather than receive it afterward. A "site-first" approach brings sites in before the protocol is locked and keeps the patient experience in view alongside sponsor goals. If delays keep surfacing after your protocol is final, this perspective shows how to design for what sites can actually deliver.